Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, compliance, and pharmacokinetics profile of estetrol monohydrate (E4)
15 mg combined with drospirenone (DRSP) 3 mg in post-menarchal participants between the age
of 12 and 17 years + 2 months.